Optitropin Oxandrolone 50 mg tablets were submitted for independent testing to verify their composition and potency. The sample, identified with no known batch number, was provided by B Ware, an individual consumer with no known affiliations to a reseller, distributor, or manufacturer. The analysis was conducted by Janoshik Analytical, an independent laboratory specializing in pharmaceutical quality control.
The laboratory results determined measured concentrations of 51.25 mg, 48.84 mg, and 47.19 mg per tablet, resulting in an average potency of 49.09 mg, which equates to 98.18% of the labeled claim, with a variance ranging from +2.5% to -5.62%. This variability is within standard pharmaceutical tolerances.
This report is published to provide transparency and promote harm reduction by offering insight into product consistency and quality.
Detailed Report
Product Overview
- Manufacturer: Optitropin
- Product Name: Oxandrolone
- Active Ingredient: Oxandrolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #48459
- Testing Ordered: 30 August 2024
- Sample Received: 4 September 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: B Ware (Individual)
- Analysis Paid For By: B Ware (Individual)
Testing Results
| Component | Specification (Label Claim) | Measured Concentrations | Accuracy (Average) | Variance |
|---|---|---|---|---|
| Oxandrolone | 50 mg per tablet | 51.25 mg, 48.84 mg, 47.19 mg | 98.18% | +2.5% to -5.62% |
Verification Details
- Verification URL: https://janoshik.com/tests/48459_1BHQELMI4VJW
Evaluation of Independent Testing
The analysis confirms that the Optitropin Oxandrolone 50 mg tablets are accurately dosed, with a slight variation within standard tolerances. The measured concentrations indicate that the product is consistently close to its labeled claim.
It is essential to recognize that this test was conducted on a single batch and may not be representative of the product’s consistency across multiple batches. Further third-party testing across various batches is recommended to ensure ongoing quality control.
Additionally, this sample was submitted by an independent consumer with no commercial affiliations, reducing the risk of selection bias typically found in manufacturer- or reseller-funded testing.
Conclusion
The results confirm that Optitropin Oxandrolone 50 mg tablets are accurately dosed, with measured concentrations ranging from 51.25 mg to 47.19 mg, averaging 98.18% of the labeled claim. This minor variation is within standard pharmaceutical tolerances, suggesting strong quality control for this batch.
Consumers are encouraged to continue verifying product quality through independent third-party testing, as this remains a crucial step in harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes only. The findings apply only to the batch tested and should not be generalized across all batches of the product. Readers are advised to critically assess all available data and consult with medical professionals before using such substances.
